Investigating gut health changes after bariatric surgery
Intestinal Permeability in Patients With Liver Fibrosis and NASH Progression Undergoing Bariatric-metabolic Surgery
This study is testing how bariatric surgery affects gut health in people with fatty liver disease to see if it helps improve their condition after losing weight.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 125 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Vienna Academic / other |
| Locations | 1 site (Vienna) |
| Trial ID | NCT05257200 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the effects of bariatric-metabolic surgery on intestinal permeability and dysbiosis in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It will assess changes in intestinal permeability before and one year after surgery, comparing patients with different levels of liver fibrosis. The study seeks to understand the relationship between gut health and liver disease progression in the context of obesity and weight loss.
Who should consider this trial
Good fit: Ideal candidates are patients with morbid obesity who are scheduled for bariatric metabolic surgery and meet the IFSO criteria.
Not a fit: Patients with other liver diseases, inflammatory bowel disease, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with NAFLD and NASH undergoing bariatric surgery.
How similar studies have performed: While there is limited systematic research on this specific topic, previous studies have shown that bariatric surgery can significantly improve liver health in obese patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with morbid obesity undergoing bariatric metabolic surgery according to the IFSO criteria, * Willingness to attend all follow-up visits * Written consent Exclusion Criteria: * other liver disease than NAFLD * presence of IBD, acute pancreatitis, amyotrophic lateral sclerosis, pregnancy
Where this trial is running
Vienna
- Medical University of Vienna — Vienna, Austria (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.